Introduction: Cross-reactivity to SARS-CoV-2 antigenic peptides has been detected on T-
cells from pre-pandemic donors due to recognition of conserved protein fragments within …

Background Prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
shedding has been described in immunocompromised coronavirus disease 2019 (COVID …

Therapeutic approaches to mitigate the severe acute lung injury associated with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have rapidly entered …

A rapidly increasing proportion of the US population, including plasma donors, now carries
SARS-CoV-2 neutralizing antibodies, a consequence of earlier COVID-19 or–for many more …

Coronavirus Disease 2019 (COVID-19), caused by a novel coronavirus, called Severe Acute
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), emerged at the end of 2019 in Wuhan …

Convalescent plasma has been a mainstay therapeutic in passive immunization for
decades. In the setting of the novel coronavirus (SARS-CoV-2), it has become widely used …

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as …

For over a century, transfusion of convalescent plasma from recovered individuals has been
tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS …

This review on COVID-19 immunotherapy enables a comparative analysis of the short-list of
currently approved major vaccines. These include the Pfizer and Moderna first mRNA …

Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19). The
World Health Organization (WHO) therefore endorses supportive care only. However …